VBI Vaccines is aiming for 2019 approval filings for its hepatitis B vaccine if a head-to-head trial against GSK's entrenched Engerix-B succeeds.

As Philippines lawmakers continue probing the country's now-controversial dengue immunization program, a former president has spoken up to defend it.

The egg-based production process might have made this season's flu shot only 10% effective.

A Sanofi exec defended its dengue shot in the Philippines on Monday as new reports showed local experts had warned against a broad vaccination push.

Preliminary results from a trio of phase 1 studies showed promise for the Zika vaccine Sanofi had previously left behind.

On the heels of a safety warning, the Philippines' FDA ordered Sanofi to pull its Dengvaxia shot from the market.

The Philippines halted its dengue vaccination program after Sanofi flagged serious risks for recipients who'd never been infected with the virus.

Already reeling from bad news on its dengue shot, Sanofi canned its phase 3 C. diff vaccine—and the $500 million-plus in sales that might have come with it.